https://www.onclive.com/watch 0.50 https://www.onclive.com/oncchats/a-close-look-at-clinical-trials-in-oncology-and-beyond 2025-01-28 0.50 https://www.onclive.com/oncchats/examining-lifu-aided-liquid-biopsy-in-glioblastoma 2023-06-11 0.50 https://www.onclive.com/oncchats/examining-the-promise-of-multicancer-early-detection-tests 2023-06-14 0.50 https://www.onclive.com/oncchats/leveraging-immunotherapy-in-gi-malignancies 2024-03-28 0.50 https://www.onclive.com/oncchats/moving-the-needle-in-undifferentiated-pleomorphic-sarcoma 2025-04-14 0.50 https://www.onclive.com/oncchats/assessing-the-promise-of-ai-in-oncology 2023-10-30 0.50 https://www.onclive.com/oncchats/optimizing-the-use-of-bispecific-antibodies-in-myeloma-and-beyond 2024-10-21 0.50 https://www.onclive.com/oncchats/taking-organoids-from-bench-to-bedside-through-endoscopy-in-pancreatic-cancer 2023-04-06 0.50 https://www.onclive.com/oncchats/traveling-through-the-lung-cancer-treatment-paradigm 2023-02-09 0.50 https://www.onclive.com/oncchats/understanding-endoscopy-in-the-realm-of-gi-cancers 2023-03-09 0.50 https://www.onclive.com/oncchats/coordinated-care-in-breast-oncology 2025-10-29 0.50 https://www.onclive.com/oncchats/immunotherapy-and-you 2023-01-16 0.50 https://www.onclive.com/oncchats/taking-action-to-individualize-ovarian-cancer-care 2023-01-16 0.50 https://www.onclive.com/oncchats/reviewing-best-practices-in-the-surgical-management-of-breast-cancer 2023-11-03 0.50 https://www.onclive.com/oncchats/empowering-community-cancer-care 2024-10-22 0.50 https://www.onclive.com/oncchats/leveraging-endoscopic-ultrasound-in-pancreatic-cancer 2023-08-29 0.50 https://www.onclive.com/oncchats/the-future-of-pathology-with-ai 2025-10-29 0.50 https://www.onclive.com/oncchats/understanding-lynch-syndrome-and-associated-cancer-risk 2023-04-29 0.50 https://www.onclive.com/oncchats/oncchats-mapping-progress-in-pancreatic-cancer-surgery 2023-08-23 0.50 https://www.onclive.com/oncchats/unpacking-data-from-pivotal-trials-in-multiple-myeloma 2023-02-09 0.50 https://www.onclive.com/peer-exchange/updates-on-her2-directed-adcs-across-solid-tumors 2024-06-25 0.50 https://www.onclive.com/peer-exchange/optimizing-outcomes-in-allogeneic-transplants 2023-12-15 0.50 https://www.onclive.com/peer-exchange/optimizing-therapy-for-patients-with-acute-and-chronic-graft-versus-host-disease-gvhd 2023-06-22 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-strategies-in-small-cell-lung-cancer 2023-06-25 0.50 https://www.onclive.com/peer-exchange/antibody-drug-conjugates-in-breast-cancer-strategies-for-toxicity-management 2022-01-18 0.50 https://www.onclive.com/peer-exchange/the-evolving-treatment-paradigm-for-stage-i-iiia-nsclc 2022-10-03 0.50 https://www.onclive.com/peer-exchange/her2-positive-colorectal-cancer-novel-approaches 2023-04-07 0.50 https://www.onclive.com/peer-exchange/recent-updates-on-the-role-of-car-t-therapy-in-lymphoma-insights-from-experts-at-jtcc 2023-12-21 0.50 https://www.onclive.com/peer-exchange/evolving-treatments-for-advanced-renal-cell-carcinoma-asco-2023-and-beyond 2023-06-25 0.50 https://www.onclive.com/peer-exchange/expert-insights-into-the-management-of-mpns 2023-07-17 0.50 https://www.onclive.com/peer-exchange/systemic-mastocytosis 2021-08-02 0.50 https://www.onclive.com/peer-exchange/recent-updates-in-the-role-of-immunotherapies-in-nsclc-translating-evidence-to-clinical-practice 2022-09-28 0.50 https://www.onclive.com/peer-exchange/matterhorn-spotlight-shaping-the-treatment-horizon-for-gastric-gastroesophageal-junction-gej-cancers 2025-06-20 0.50 https://www.onclive.com/peer-exchange/navigating-the-future-of-cutaneous-squamous-cell-carcinoma-cscc-an-expert-discussion-on-modern 2025-11-10 0.50 https://www.onclive.com/peer-exchange/systemic-therapy-for-hcc-a-rapidly-evolving-landscape 2021-08-06 0.50 https://www.onclive.com/peer-exchange/evolving-treatments-of-metastatic-crc-insights-from-asco-2024 2024-06-25 0.50 https://www.onclive.com/peer-exchange/advancements-in-the-management-of-gynecological-cancers-esmo-2024 2024-09-30 0.50 https://www.onclive.com/peer-exchange/recent-data-and-new-learnings-myeloproliferative-neoplasms 2022-12-22 0.50 https://www.onclive.com/peer-exchange/key-clinical-updates-with-her2-targeting-therapies 2025-11-03 0.50 https://www.onclive.com/peer-exchange/esmo-2024-treatment-breakthroughs-in-pretreated-patients-with-advanced-or-metastatic-nsclc-with 2024-10-15 0.50 https://www.onclive.com/peer-exchange/key-updates-in-lung-cancer-in-2021 2021-10-29 0.50 https://www.onclive.com/peer-exchange/evolving-management-landscape-for-advanced-prostate-cancer 2021-08-12 0.50 https://www.onclive.com/peer-exchange/recent-advances-in-the-treatment-of-chronic-lymphocytic-leukemia 2022-07-19 0.50 https://www.onclive.com/peer-exchange/antibody-drug-conjugate-therapy-at-the-forefront-of-triple-negative-breast-cancer 2026-06-30 0.50 https://www.onclive.com/peer-exchange/data-updates-in-the-treatment-of-resectable-cutaneous-squamous-cell-carcinoma 2023-03-15 0.50 https://www.onclive.com/peer-exchange/evolving-approaches-in-small-cell-lung-cancer 2021-07-12 0.50 https://www.onclive.com/peer-exchange/unpacking-key-data-from-ash-2024 2025-04-08 0.50 https://www.onclive.com/peer-exchange/global-perspectives-in-the-treatment-of-egfr-mutant-resectable-and-advanced-nsclc 2022-02-09 0.50 https://www.onclive.com/peer-exchange/advances-in-the-management-of-pediatric-low-grade-glioma-plgg-a-focus-on-optimizing-treatment 2026-04-20 0.50 https://www.onclive.com/peer-exchange/asco-2024-immunotherapy-for-the-treatment-of-small-cell-lung-cancer 2024-06-21 0.50 https://www.onclive.com/peer-exchange/adcs-in-the-treatment-of-breast-cancer-and-gastric-cancer-and-managing-aes-associated-with-adcs 2022-08-18 0.50 https://www.onclive.com/peer-exchange/latest-advances-in-alk-positive-and-braf-positive-v600e-nsclc-efficacy-updates-brain-metastases 2024-10-25 0.50 https://www.onclive.com/peer-exchange/current-practices-and-future-directions-for-treatment-of-graft-vs-host-disease 2021-07-16 0.50 https://www.onclive.com/peer-exchange/clinical-insights-on-r-r-follicular-lymphoma-ash-2024-highlights 2025-06-11 0.50 https://www.onclive.com/peer-exchange/early-stage-non-small-cell-lung-cancer-evidence-based-practice-updates 2025-09-26 0.50 https://www.onclive.com/peer-exchange/advances-in-the-treatment-of-multiple-myeloma-highlights-from-ash-2023-and-beyond 2024-01-23 0.50 https://www.onclive.com/peer-exchange/evolving-practice-patterns-for-multiple-myeloma 2021-07-13 0.50 https://www.onclive.com/peer-exchange/evolving-role-of-antibody-drug-conjugates-in-gynecologic-cancers 2026-04-27 0.50 https://www.onclive.com/peer-exchange/eha-2024-updates-in-the-treatment-of-cll 2024-06-27 0.50 https://www.onclive.com/peer-exchange/optimizing-treatment-strategies-in-hr-positive-her2-negative-breast-cancer-sequencing-targeted 2026-06-23 0.50 https://www.onclive.com/peer-exchange/optimizing-early-stage-nsclc-management-a-multidisciplinary-perspective 2025-04-17 0.50 https://www.onclive.com/peer-exchange/asco-2025-current-insights-and-emerging-approaches-in-managing-treatment-resistant-metastatic 2025-06-10 0.50 https://www.onclive.com/peer-exchange/test-evidence-based-strategies-for-selecting-and-sequencing-systemic-therapies-in-rcc-highlights 2022-10-05 0.50 https://www.onclive.com/peer-exchange/applying-new-data-to-treatment-selection-in-patients-with-relapsed-refractory-diffuse-large-b-ce 2022-06-29 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-paradigms-and-recent-data-in-hr-her2-breast-cancer 2023-11-26 0.50 https://www.onclive.com/peer-exchange/progress-in-immunotherapy-and-precision-medicine-key-insights-from-jtcc-at-ash-2024 2024-12-18 0.50 https://www.onclive.com/peer-exchange/updates-in-the-treatment-of-her2-positive-and-her2-low-breast-cancer 2022-06-22 0.50 https://www.onclive.com/peer-exchange/recent-advances-in-the-treatment-of-prostate-cancer 2022-03-29 0.50 https://www.onclive.com/peer-exchange/asco-2025-modern-approaches-to-metastatic-melanoma-navigating-the-treatment-landscape 2025-07-01 0.50 https://www.onclive.com/peer-exchange/clinical-advances-in-hormone-receptor-positive-breast-cancer 2021-10-28 0.50 https://www.onclive.com/peer-exchange/therapeutic-outlook-in-dlbcl-evaluating-treatment-sequencing-from-front-line-to-relapsed 2024-12-20 0.50 https://www.onclive.com/peer-exchange/updates-in-her2-early-and-metastatic-breast-cancer 2023-01-20 0.50 https://www.onclive.com/peer-exchange/current-practices-and-future-directions-for-treatment-of-egfr-mutated-lung-cancer 2021-05-27 0.50 https://www.onclive.com/peer-exchange/optimizing-therapy-for-patients-radioactive-iodine-refractory-differentiated-thyroid-cancer 2024-03-22 0.50 https://www.onclive.com/peer-exchange/ash-2024-breakthrough-insights-on-car-t-cell-therapy-for-relapsed-refractory-all 2025-05-29 0.50 https://www.onclive.com/peer-exchange/egfr-mutant-advanced-nsclc-frontline-choices-sequencing-and-emerging-strategies 2026-06-24 0.50 https://www.onclive.com/peer-exchange/optimizing-treatment-intensification-in-metastatic-castration-sensitive-prostate-cancer-evidence 2026-03-11 0.50 https://www.onclive.com/peer-exchange/advances-in-the-treatment-of-urothelial-carcinomas 2023-03-23 0.50 https://www.onclive.com/peer-exchange/a-new-wave-of-progress-in-the-treatment-of-multiple-myeloma 2022-06-22 0.50 https://www.onclive.com/peer-exchange/refining-treatment-approaches-for-chronic-lymphocytic-leukemia 2021-06-28 0.50 https://www.onclive.com/peer-exchange/recent-advances-in-the-treatment-of-advanced-her2-breast-cancer-sabcs-2024 2025-06-19 0.50 https://www.onclive.com/peer-exchange/advancing-biomarker-driven-strategies-in-nsclc-exploring-the-emerging-role-of-qcs-and-trop2-nmr 2025-08-27 0.50 https://www.onclive.com/peer-exchange/her2-breast-cancer-applying-recent-data-updates-to-clinical-practice 2024-01-23 0.50 https://www.onclive.com/peer-exchange/expert-perspectives-and-insights-into-the-evolving-treatment-of-refractory-metastatic-colorectal 2024-02-21 0.50 https://www.onclive.com/peer-exchange/the-evolving-treatment-paradigm-of-hepatocellular-carcinoma-an-expert-case-based-discussion 2022-10-17 0.50 https://www.onclive.com/peer-exchange/precision-medicine-a-collaborative-and-multidisciplinary-approach-to-identifying-biomarkers 2023-02-07 0.50 https://www.onclive.com/peer-exchange/current-and-future-trends-in-myeloproliferative-neoplasms 2022-06-29 0.50 https://www.onclive.com/peer-exchange/the-evolving-landscape-of-differentiated-thyroid-cancer-treatment 2021-12-21 0.50 https://www.onclive.com/peer-exchange/diagnosis-and-treatment-of-biliary-tract-cancers 2023-02-13 0.50 https://www.onclive.com/peer-exchange/utilization-of-mrd-ctdna-testing-in-bladder-cancer-and-other-gu-malignancies 2026-05-04 0.50 https://www.onclive.com/peer-exchange/asco-2025-optimizing-breast-cancer-surveillance-with-ctdna-testing-transforming-early-detection 2025-06-09 0.50 https://www.onclive.com/peer-exchange/navigating-new-treatment-options-in-relapsed-refractory-diffuse-large-b-cell-lymphoma 2022-01-18 0.50 https://www.onclive.com/peer-exchange/asco-2025-expert-perspectives-in-gastrointestinal-stromal-tumor-treatment 2025-06-19 0.50 https://www.onclive.com/peer-exchange/a-new-wave-of-progress-in-the-treatment-of-renal-cell-carcinoma-highlights-from-asco-gu-2023-and 2023-03-09 0.50 https://www.onclive.com/peer-exchange/oncodrivers-in-advanced-or-metastatic-nsclc-current-and-future-standards-of-care 2025-06-16 0.50 https://www.onclive.com/peer-exchange/expert-insights-on-an-evolving-treatment-landscape-in-multiple-myeloma-updates-from-eha-2025 2025-06-25 0.50 https://www.onclive.com/peer-exchange/recent-data-and-new-learnings-in-myeloproliferative-neoplasm 2022-12-22 0.50 https://www.onclive.com/peer-exchange/updates-in-immunotherapy-for-non-small-cell-lung-cancer 2021-06-30 0.50 https://www.onclive.com/peer-exchange/expert-perspectives-on-the-evolving-treatment-landscape-of-multiple-myeloma 2022-12-22 0.50 https://www.onclive.com/peer-exchange/advances-in-the-management-of-graft-versus-host-disease 2022-01-10 0.50 https://www.onclive.com/peer-exchange/state-of-the-art-care-for-her2-metastatic-breast-cancer 2021-07-06 0.50 https://www.onclive.com/peer-exchange/targeting-nsclc-with-precision-evaluation-of-the-emerging-role-of-antibody-drug-conjugates 2024-06-21 0.50 https://www.onclive.com/peer-exchange/expert-perspectives-current-and-emerging-therapies-for-acute-myeloid-leukemia-aml 2023-06-22 0.50 https://www.onclive.com/peer-exchange/treatment-approaches-in-non-melanoma-skin-cancers 2021-11-19 0.50 https://www.onclive.com/peer-exchange/updates-in-the-treatment-of-hr-breast-cancer 2024-06-21 0.50 https://www.onclive.com/peer-exchange/antibody-drug-conjugates-in-cancer-treatment 2023-09-29 0.50 https://www.onclive.com/peer-exchange/advancements-in-the-treatment-and-management-of-sclc-updates-from-asco-2025 2025-06-10 0.50 https://www.onclive.com/peer-exchange/advancing-care-in-hr-positive-breast-cancer-integrating-cdk4-6-inhibition-serds-and-early 2025-12-18 0.50 https://www.onclive.com/peer-exchange/her2-alterations-in-non-small-cell-lung-cancer 2022-09-13 0.50 https://www.onclive.com/peer-exchange/the-evolving-field-of-biomarker-testing-in-solid-tumors 2022-08-30 0.50 https://www.onclive.com/peer-exchange/the-evolving-treatment-paradigm-of-advanced-non-small-cell-lung-cancer-where-are-we-in-2023 2023-11-20 0.50 https://www.onclive.com/peer-exchange/recent-advances-in-the-treatment-of-chronic-gvhdgvhd-ash-2024 2025-05-29 0.50 https://www.onclive.com/peer-exchange/her2-breast-cancer-applying-recent-data-updates-at-asco-2024-into-clinical-practice 2024-06-24 0.50 https://www.onclive.com/peer-exchange/advancing-treatments-for-bladder-cancer-insights-from-asco-gu-2024 2024-02-23 0.50 https://www.onclive.com/peer-exchange/updates-in-the-treatment-of-myelodysplastic-syndrome 2021-07-06 0.50 https://www.onclive.com/peer-exchange/advances-in-testing-and-targeted-therapy-for-nsclc-translating-evidence-to-clinical-practice 2022-06-27 0.50 https://www.onclive.com/peer-exchange/experts-perspectives-navigating-newly-diagnosed-mm-to-early-relapse 2024-10-18 0.50 https://www.onclive.com/peer-exchange/ash-2024-updates-in-the-treatment-of-cll 2025-01-03 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-sequencing-and-practical-management-in-advanced-renal-cell-carcinoma 2026-03-10 0.50 https://www.onclive.com/peer-exchange/circulating-tumor-dna-and-minimal-residual-disease-testing-across-solid-tumors 2026-06-22 0.50 https://www.onclive.com/peer-exchange/from-sequential-tkis-to-combination-therapy-in-advanced-gist-current-standards-peak-phase-3-data 2026-06-17 0.50 https://www.onclive.com/peer-exchange/optimizing-ctcl-care-expert-perspectives-on-patient-centered-approaches 2025-07-31 0.50 https://www.onclive.com/peer-exchange/new-treatment-options-for-relapsed-recurrent-dlbcl-impact-on-sequencing-therapeutic-choices 2024-06-25 0.50 https://www.onclive.com/peer-exchange/advances-in-the-management-of-chemotherapy-induced-neutropenia 2021-10-22 0.50 https://www.onclive.com/peer-exchange/prostate-cancer-treatment-updates 2022-06-27 0.50 https://www.onclive.com/peer-exchange/the-evolving-treatment-landscape-of-renal-cell-carcinoma-highlights-from-esmo-2022-and-beyond 2022-09-29 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-strategies-in-acute-myeloid-leukemia 2025-12-16 0.50 https://www.onclive.com/peer-exchange/translating-recent-evidence-to-the-real-world-management-of-relapsed-refractory-dlbcl 2023-06-19 0.50 https://www.onclive.com/peer-exchange/addressing-disparities-in-multiple-myeloma-care-among-racial-and-ethnic-minority-populations 2022-09-21 0.50 https://www.onclive.com/peer-exchange/gynecological-cancers-treatment-updates-and-expert-perspectives 2025-09-29 0.50 https://www.onclive.com/peer-exchange/evolving-strategies-in-neuroendocrine-tumor-management 2026-06-16 0.50 https://www.onclive.com/peer-exchange/lower-risk-myelodysplastic-syndromes-lr-mds-highlights-from-eha-2024 2024-07-08 0.50 https://www.onclive.com/peer-exchange/optimizing-early-stage-nsclc-management-through-multidisciplinary-strategies-asco-2025 2025-06-25 0.50 https://www.onclive.com/peer-exchange/evolving-first-line-maintenance-and-sequencing-strategies-in-extensive-stage-small-cell-lung 2026-06-22 0.50 https://www.onclive.com/peer-exchange/egfr-mutated-mnsclc-sharing-clinical-insights-and-best-practices 2025-09-17 0.50 https://www.onclive.com/peer-exchange/asco-gu-2024-updates-in-the-treatment-of-advanced-renal-cell-carcinoma 2024-02-21 0.50 https://www.onclive.com/peer-exchange/recent-updates-in-the-role-of-io-in-nsclc-translating-evidence-to-clinical-practice 2023-04-21 0.50 https://www.onclive.com/peer-exchange/esmo-2023-expert-perspectives-and-insights-into-the-testing-and-treatment-of-melanoma 2023-11-14 0.50 https://www.onclive.com/peer-exchange/new-treatment-options-for-dlbcl-impact-on-sequencing-therapeutic-choices 2023-12-19 0.50 https://www.onclive.com/peer-exchange/therapy-options-in-hr-positive-her2-negative-breast-cancer 2022-06-27 0.50 https://www.onclive.com/peer-exchange/evolving-testing-and-treatment-strategies-in-metastatic-colorectal-cancer-tracking-test 2023-06-26 0.50 https://www.onclive.com/peer-exchange/esmo-2024-targeting-the-treatment-challenges-of-small-cell-lung-cancer 2024-09-30 0.50 https://www.onclive.com/peer-exchange/evolving-first-line-treatment-strategies-in-her2-positive-metastatic-gastroesophageal 2026-04-28 0.50 https://www.onclive.com/peer-exchange/acute-myeloid-leukemia-2021-perspectives-on-testing-systemic-therapies-and-transplantation 2021-07-21 0.50 https://www.onclive.com/peer-exchange/advancing-precision-care-in-unresectable-and-metastatic-colorectal-cancer 2026-01-23 0.50 https://www.onclive.com/peer-exchange/recent-advances-in-cervical-cancer-treatment 2021-10-13 0.50 https://www.onclive.com/peer-exchange/actionable-mutations-in-nsclc-expert-perspectives-in-testing-and-targeted-therapy 2022-04-12 0.50 https://www.onclive.com/peer-exchange/diagnosis-and-treatment-of-metastatic-colorectal-cancer-with-a-focus-on-her2-positive-disease 2023-02-08 0.50 https://www.onclive.com/peer-exchange/metastatic-castration-sensitive-prostate-cancer-evolving-management-with-new-data-from-asco-2025 2025-06-27 0.50 https://www.onclive.com/peer-exchange/advancements-in-the-management-of-r-r-aml-ash-2024 2025-05-29 0.50 https://www.onclive.com/peer-exchange/translating-evidence-to-practice-to-improve-outcomes-in-relapsed-refractory-diffuse-large-b-cell 2023-02-02 0.50 https://www.onclive.com/peer-exchange/updates-in-treatment-approaches-for-ovarian-and-endometrial-cancers 2023-06-29 0.50 https://www.onclive.com/peer-exchange/treatment-of-chronic-lymphocytic-leukemia-insights-into-btk-and-bcl-inhibitor-sequencing 2025-12-18 0.50 https://www.onclive.com/peer-exchange/optimizing-therapy-for-ovarian-cancer-recent-data-highlights 2022-10-05 0.50 https://www.onclive.com/peer-exchange/treatment-advancements-in-newly-diagnosed-and-relapsed-refractory-in-multiple-myeloma 2025-06-20 0.50 https://www.onclive.com/peer-exchange/transforming-outcomes-in-al-amyloidosis-with-precision-medicine-and-targeted-therapies 2024-01-19 0.50 https://www.onclive.com/peer-exchange/asco-2024-updates-in-the-treatment-of-advanced-renal-cell-carcinoma 2024-06-21 0.50 https://www.onclive.com/peer-exchange/evolving-practice-patterns-for-clear-cell-renal-cell-carcinoma 2021-07-06 0.50 https://www.onclive.com/peer-exchange/advancing-care-in-small-cell-lung-cancer-optimizing-immunotherapy-managing-toxicities-and 2025-09-17 0.50 https://www.onclive.com/peer-exchange/frontline-and-sequential-strategies-in-her2-positive-breast-cancer-integrating-emerging-evidence 2026-02-16 0.50 https://www.onclive.com/peer-exchange/optimizing-treatment-of-desmoid-tumor-through-multidisciplinary-strategies 2026-02-27 0.50 https://www.onclive.com/peer-exchange/the-changing-treatment-paradigm-of-her2-metastatic-breast-cancer 2022-03-30 0.50 https://www.onclive.com/peer-exchange/integrating-ocular-toxicity-management-into-routine-care-for-solid-tumor-patients-receiving-treatment-with-adcs 2025-12-15 0.50 https://www.onclive.com/peer-exchange/polycythemia-vera-and-myelofibrosis-current-and-future-standards-of-care 2024-01-19 0.50 https://www.onclive.com/peer-exchange/recent-updates-in-the-role-of-immunotherapies-in-early-nsclc-translating-evidence-to-clinical 2023-06-23 0.50 https://www.onclive.com/peer-exchange/exploring-biliary-tract-cancer-top-takeaways-from-asco-gi-2025 2025-02-19 0.50 https://www.onclive.com/peer-exchange/the-changing-landscape-for-her2-advanced-metastatic-breast-cancer 2022-05-16 0.50 https://www.onclive.com/peer-exchange/data-driven-decision-making-in-advanced-breast-cancer-hr-breast-cancer-updates 2023-02-16 0.50 https://www.onclive.com/peer-exchange/evolving-treatments-in-hepatocellular-carcinoma-updates-from-asco-gi-2024 2024-05-16 0.50 https://www.onclive.com/peer-exchange/a-new-wave-of-progress-in-the-treatment-of-hepatocellular-cancer 2022-03-08 0.50 https://www.onclive.com/peer-exchange/emerging-treatment-considerations-in-hcc-an-expert-case-based-discussion 2022-06-22 0.50 https://www.onclive.com/peer-exchange/the-evolving-treatment-paradigm-in-multiple-myeloma-recent-updates 2023-06-20 0.50 https://www.onclive.com/peer-exchange/egfr-mutated-nsclc-treatment-advances-and-highlights-from-asco-2025 2025-06-10 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-strategies-in-advanced-non-small-cell-lung-cancer 2026-06-23 0.50 https://www.onclive.com/peer-exchange/updates-in-the-management-of-stage-iii-non-small-cell-lung-cancer-nsclc 2024-06-25 0.50 https://www.onclive.com/peer-exchange/key-updates-in-non-metastatic-and-metastatic-prostate-cancer-treatment 2023-03-06 0.50 https://www.onclive.com/peer-exchange/navigating-the-evolving-treatment-landscape-in-her2-non-small-cell-lung-cancer 2024-04-22 0.50 https://www.onclive.com/peer-exchange/recent-advances-in-the-treatment-of-chronic-lymphocytic-leukemia-cll 2022-07-19 0.50 https://www.onclive.com/peer-exchange/optimizing-therapy-for-patients-with-advanced-renal-cell-carcinoma 2023-10-30 0.50 https://www.onclive.com/peer-exchange/asco-gu-2025-optimizing-treatment-selection-and-clinical-decision-making-in-advanced-rcc 2025-02-27 0.50 https://www.onclive.com/peer-exchange/patient-profiles-in-her2-positive-breast-cancer 2022-04-01 0.50 https://www.onclive.com/peer-exchange/advanced-endometrial-cancer-treatment-optimization 2022-11-18 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-paradigms-in-endometrial-cancer 2021-05-11 0.50 https://www.onclive.com/peer-exchange/transforming-outcomes-in-cll-highlights-from-the-ash-2022-meeting 2023-01-24 0.50 https://www.onclive.com/peer-exchange/highlighting-key-treatment-updates-in-the-management-of-neuroendocrine-tumors 2025-11-13 0.50 https://www.onclive.com/peer-exchange/advancements-in-treatment-selection-and-sequencing-in-her2-positive-metastatic-breast-cancer 2025-09-12 0.50 https://www.onclive.com/peer-exchange/ash-2024-global-updates-in-the-management-of-chronic-lymphocytic-leukemia 2025-05-29 0.50 https://www.onclive.com/peer-exchange/clinical-updates-in-adc-therapy-for-triple-negative-breast-cancer 2026-01-05 0.50 https://www.onclive.com/peer-exchange/emerging-treatment-considerations-in-hepatocellular-carcinoma-an-expert-case-based-discussion 2021-11-10 0.50 https://www.onclive.com/peer-exchange/esmo-2024-treatment-of-uhcc 2024-10-07 0.50 https://www.onclive.com/peer-exchange/treatment-approaches-and-sequencing-strategies-in-differentiated-thyroid-cancer 2023-04-17 0.50 https://www.onclive.com/peer-exchange/advances-in-treatment-and-management-of-immune-thrombocytopenia 2022-06-30 0.50 https://www.onclive.com/peer-exchange/updates-in-hr-her2--advanced-or-metastatic-breast-cancer 2021-10-11 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-strategies-in-pancreatic-cancer-differentiating-nalirifox-from-folfirinox 2026-01-20 0.50 https://www.onclive.com/peer-exchange/optimizing-care-for-ros1-positive-non-small-cell-lung-cancer 2026-03-27 0.50 https://www.onclive.com/peer-exchange/utilizing-different-mechanisms-of-action-for-treatment-of-chronic-graft-versus-host-disease 2024-01-09 0.50 https://www.onclive.com/peer-exchange/her2-breast-cancer-recent-data-updates-and-key-advances 2023-06-28 0.50 https://www.onclive.com/peer-exchange/optimizing-treatment-strategies-in-diffuse-large-b-cell-lymphoma 2026-06-30 0.50 https://www.onclive.com/peer-exchange/recent-advances-in-the-treatment-of-relapsed-refractory-multiple-myeloma 2022-02-09 0.50 https://www.onclive.com/peer-exchange/navigating-multiple-myeloma-from-newly-diagnosed-to-relapsed-refractory 2025-06-19 0.50 https://www.onclive.com/peer-exchange/the-evolving-treatment-landscape-of-small-cell-lung-cancer 2022-07-19 0.50 https://www.onclive.com/peer-exchange/clinical-perspectives-on-the-treatment-of-neuroendocrine-tumors 2025-06-19 0.50 https://www.onclive.com/peer-exchange/recent-advances-in-the-treatment-of-mantle-cell-lymphoma 2023-01-06 0.50 https://www.onclive.com/peer-exchange/precision-medicine-biomarker-testing-and-uncommon-egfr-mutations-in-nsclc 2023-11-16 0.50 https://www.onclive.com/peer-exchange/egfr-mutant-nsclc-expert-perspectives-in-testing-and-targeted-therapy 2024-01-23 0.50 https://www.onclive.com/peer-exchange/myelodysplastic-syndromes-mds-recent-updates-and-evolving-treatment-paradigms 2023-06-22 0.50 https://www.onclive.com/peer-exchange/redefining-allogeneic-transplants-and-cellular-therapy-key-takeaways-from-ebmt-2025 2025-09-26 0.50 https://www.onclive.com/peer-exchange/acute-lymphoblastic-leukemia-the-current-and-future-state-of-care 2023-02-03 0.50 https://www.onclive.com/peer-exchange/elcc-updates-in-immunotherapy-and-beyond-for-non-small-cell-lung-cancer 2023-04-26 0.50 https://www.onclive.com/peer-exchange/ash-2024-polycythemia-vera-and-myelofibrosis-current-and-future-standards-of-care 2025-02-07 0.50 https://www.onclive.com/peer-exchange/optimizing-the-management-of-metastatic-uveal-melanoma-from-molecular-diagnosis-to-emerging 2026-06-23 0.50 https://www.onclive.com/peer-exchange/the-evolving-landscape-of-biliary-tract-cancers 2022-09-19 0.50 https://www.onclive.com/peer-exchange/transforming-outcomes-in-hepatocellular-carcinoma-expert-insights-on-applying-evidence-to 2023-02-17 0.50 https://www.onclive.com/peer-exchange/bridging-community-and-academic-practice-multidisciplinary-approaches-to-diffuse-midline-gliomas 2025-11-05 0.50 https://www.onclive.com/peer-exchange/key-advances-in-diagnosis-treatment-and-management-of-mds 2023-01-18 0.50 https://www.onclive.com/peer-exchange/ash-2023-exploring-therapeutic-advancements-for-chronic-lymphocytic-leukemia 2024-01-12 0.50 https://www.onclive.com/peer-exchange/recent-updates-in-the-treatment-of-follicular-lymphoma-and-mantle-cell-lymphoma 2024-01-02 0.50 https://www.onclive.com/peer-exchange/balancing-innovation-and-drug-pricing-in-global-cancer-care 2021-08-09 0.50 https://www.onclive.com/peer-exchange/expert-perspectives-on-the-current-state-of-graft-vs-host-disease 2023-01-12 0.50 https://www.onclive.com/peer-exchange/the-expanding-field-of-gvhd 2022-07-06 0.50 https://www.onclive.com/peer-exchange/evolution-of-precision-medicine-in-non-small-cell-lung-cancer 2021-07-01 0.50 https://www.onclive.com/peer-exchange/immunotherapy-in-endometrial-cancer-practice-changing-insights-from-ruby-and-beyond 2026-04-27 0.50 https://www.onclive.com/peer-exchange/optimizing-treatment-strategies-in-chronic-lymphocytic-leukemia 2026-06-26 0.50 https://www.onclive.com/peer-exchange/the-evolving-treatment-landscape-in-multiple-myeloma-an-expert-case-based-discussion 2023-03-09 0.50 https://www.onclive.com/peer-exchange/advances-in-biomarker-testing-and-targeted-therapies-in-nsclc 2023-08-14 0.50 https://www.onclive.com/peer-exchange/adc-adverse-effect-management-in-breast-and-lung-cancer-practical-strategies-for-the-clinic 2026-03-31 0.50 https://www.onclive.com/peer-exchange/hr-breast-cancer-treatment-advances-and-highlights-from-asco-2025 2025-06-16 0.50 https://www.onclive.com/peer-exchange/recent-advances-in-treating-endometrial-and-cervical-cancers 2023-11-22 0.50 https://www.onclive.com/peer-exchange/recent-updates-on-management-of-diffuse-large-b-cell-lymphoma 2021-07-12 0.50 https://www.onclive.com/peer-exchange/updates-in-management-of-myeloproliferative-neoplasms 2021-07-14 0.50 https://www.onclive.com/peer-exchange/chronic-lymphocytic-leukemia-evolving-management-with-new-data-from-eha-2025 2025-06-30 0.50 https://www.onclive.com/peer-exchange/updates-in-the-treatment-of-hr-her2-breast-cancer 2025-06-19 0.50 https://www.onclive.com/peer-exchange/evolving-testing-and-treatment-strategies-in-metastatic-colorectal-cancer 2023-06-21 0.50 https://www.onclive.com/peer-exchange/expert-perspectives-on-current-and-emerging-therapies-for-aml 2023-01-20 0.50 https://www.onclive.com/peer-exchange/radioligand-equivalents-advancing-nomenclature-and-understanding-the-505-b-2-pathway-in 2026-06-30 0.50 https://www.onclive.com/peer-exchange/hepatocellular-carcinoma-hcc-recent-updates-and-evolving-treatment-paradigms 2023-07-11 0.50 https://www.onclive.com/peer-exchange/advances-in-mrd-testing-for-informed-crc-treatment 2024-03-18 0.50 https://www.onclive.com/peer-exchange/evidence-based-strategies-for-selecting-and-sequencing-systemic-therapies-in-rcc-highlights-from 2022-03-15 0.50 https://www.onclive.com/peer-exchange/optimizing-homologous-recombination-deficiency-hrd-testing-paradigms-in-ovarian-cancer 2023-08-01 0.50 https://www.onclive.com/peer-exchange/advancements-in-the-treatment-of-desmoid-tumors 2023-12-20 0.50 https://www.onclive.com/peer-exchange/a-review-of-unmet-needs-and-ways-to-provide-optimal-care-in-multiple-myeloma 2023-08-21 0.50 https://www.onclive.com/peer-exchange/expert-perspectives-and-insights-into-car-t-cell-therapy-in-rrall 2024-06-27 0.50 https://www.onclive.com/peer-exchange/updates-in-the-treatment-of-b-cell-lymphoma-focus-on-mcl-fl-and-mzl 2021-12-22 0.50 https://www.onclive.com/peer-exchange/advancing-muscle-invasive-bladder-cancer-testing-and-clinical-integration 2025-11-12 0.50 https://www.onclive.com/peer-exchange/myeloproliferative-neoplasms 2022-02-09 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-landscape-in-myelodysplastic-syndromes 2024-01-30 0.50 https://www.onclive.com/peer-exchange/updates-in-treatment-approaches-for-prostate-cancer 2023-06-26 0.50 https://www.onclive.com/peer-exchange/oncodrivers-in-advanced-or-metastatic-nsclc-current-and-future-standards-of-care-2 2025-11-06 0.50 https://www.onclive.com/peer-exchange/advances-in-the-treatment-of-malignant-melanoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/acute-myeloid-leukemia-evolving-through-targeted-therapies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/expanding-treatment-options-for-her2-positive-breast-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/personalized-approaches-to-treatment-of-metastatic-colorectal-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/updates-on-biomarker-directed-therapy-for-solid-tumors-focus-on-ntrk-ret-and-nrg-1 2021-04-15 0.50 https://www.onclive.com/peer-exchange/new-first-line-combination-therapies-in-advanced-rcc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/updates-in-the-management-of-myeloproliferative-neoplasms 2021-04-15 0.50 https://www.onclive.com/peer-exchange/clinical-updates-on-the-treatment-of-advanced-cholangiocarcinoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/multiple-myeloma-management-in-2021 2021-04-15 0.50 https://www.onclive.com/peer-exchange/evolving-practice-patterns-for-advanced-clear-cell-renal-cell-carcinoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/practical-perspectives-in-the-treatment-of-small-cell-lung-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/integrating-newer-therapies-into-management-of-adult-all 2021-04-15 0.50 https://www.onclive.com/peer-exchange/improving-outcomes-in-relapsed-refractory-diffuse-large-b-cell-lymphoma 2021-07-27 0.50 https://www.onclive.com/peer-exchange/evolving-therapies-in-chronic-lymphocytic-leukemia 2021-04-15 0.50 https://www.onclive.com/peer-exchange/expert-perspectives-on-advanced-hormone-receptor-positive-breast-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/hepatocellular-carcinoma-practical-implications-of-emerging-data 2021-04-15 0.50 https://www.onclive.com/peer-exchange/clinical-updates-on-relapsed-refractory-follicular-lymphoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/global-updates-in-advanced-gastric-cancer-from-esmo-2020 2021-04-15 0.50 https://www.onclive.com/peer-exchange/the-expanding-role-of-car-t-cells-in-lymphoma-and-leukemia 2021-04-15 0.50 https://www.onclive.com/peer-exchange/video-series-test 2021-04-15 0.50 https://www.onclive.com/peer-exchange/triple-negative-breast-cancer-expert-perspectives-on-recent-advances 2021-04-15 0.50 https://www.onclive.com/peer-exchange/refining-treatment-approaches-for-her2-breast-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/precision-medicine-key-updates-for-treatment-of-nsclc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/updates-in-the-management-of-hairy-cell-leukemia 2021-04-15 0.50 https://www.onclive.com/peer-exchange/updates-in-the-management-of-graft-versus-host-disease 2021-04-15 0.50 https://www.onclive.com/peer-exchange/the-evolving-treatment-landscape-in-relapsed-refractory-diffuse-large-b-cell-lymphoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-endometrial-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/transplant-associated-thrombotic-microangiopathy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/updates-in-systemic-therapy-for-non-metastatic-lung-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/practical-implications-for-treatment-strategies-in-advanced-ovarian-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-clear-cell-renal-cell-carcinoma-putting-advances-into-practice 2021-04-15 0.50 https://www.onclive.com/peer-exchange/2015-update-onc-colorectal-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/2016-advancements-breast-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/a-rapid-shift-in-treatment-for-cll 2021-04-15 0.50 https://www.onclive.com/peer-exchange/acute-leukemia 2021-04-15 0.50 https://www.onclive.com/peer-exchange/acute-myeloid-leukemia 2021-04-15 0.50 https://www.onclive.com/peer-exchange/adult-immune-thrombocytopenia-purpura 2021-04-15 0.50 https://www.onclive.com/peer-exchange/adult-itp-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/adult-itp-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-breast-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-breast-cancer-evolving-concepts 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-breast-cancer-update 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-breast-cancer-updates 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-colon-rectal-cancers 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-crc-evolving-strategies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-crc-extending-survival 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-crc-strategies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-dtc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-gastric-gastro-esophageal-cancers 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-gi-cancers 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-hcc-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-hnscc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-kidney-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-lung-adenocarcinoma-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-lung-cancer-a-year-in-review 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-lung-cancer-emerging-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-melanoma-cases 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-melanoma-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-melanoma-paradigms 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-nonsquamous-nsclc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-ovarian-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-ovarian-cancer-strategies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-ovarian-cancer-systemic-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-prostate-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-renal-cell-carcinoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-urothelial-carcinoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advances-in-melanoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/aml-personalized-medicine-path 2021-04-15 0.50 https://www.onclive.com/peer-exchange/aml-precision-medicine 2021-04-15 0.50 https://www.onclive.com/peer-exchange/aml-targeted-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/angiogenesis-lung-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/anti-angiogenic-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/b-cell-malignancies-updates 2021-04-15 0.50 https://www.onclive.com/peer-exchange/bone-health 2021-04-15 0.50 https://www.onclive.com/peer-exchange/breakthrough-pain 2021-04-15 0.50 https://www.onclive.com/peer-exchange/breast-cancer-advancements 2021-04-15 0.50 https://www.onclive.com/peer-exchange/breast-cancer-expanding-options 2021-04-15 0.50 https://www.onclive.com/peer-exchange/breast-cancer-therapies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/breast10-care-continuum 2021-04-15 0.50 https://www.onclive.com/peer-exchange/breast11-global-perspectives 2021-04-15 0.50 https://www.onclive.com/peer-exchange/breast9-precision-medicine 2021-04-15 0.50 https://www.onclive.com/peer-exchange/cart-in-hematological-malignancies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/cart-therapy-bcell 2021-04-15 0.50 https://www.onclive.com/peer-exchange/case-based-prostate-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/changing-landscape-in-mcl 2021-04-15 0.50 https://www.onclive.com/peer-exchange/chronic-lymphocytic-leukemia 2021-04-15 0.50 https://www.onclive.com/peer-exchange/chronic-myeloid-leukemia 2021-04-15 0.50 https://www.onclive.com/peer-exchange/cinv-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/cll-systemic-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/cml-management-advances 2021-04-15 0.50 https://www.onclive.com/peer-exchange/cml-perspectives 2021-04-15 0.50 https://www.onclive.com/peer-exchange/colorectal-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/crc-improving-outcomes 2021-04-15 0.50 https://www.onclive.com/peer-exchange/crc-review 2021-04-15 0.50 https://www.onclive.com/peer-exchange/crc-therapies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/crc8-systemic-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/crc9-advanced 2021-04-15 0.50 https://www.onclive.com/peer-exchange/crpc-cases 2021-04-15 0.50 https://www.onclive.com/peer-exchange/dlbcl-emerging-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/early-breast-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/emergence-of-biosimilars 2021-04-15 0.50 https://www.onclive.com/peer-exchange/emerging-therapies-in-prostate-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/evolution-car-t-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/evolving-concepts-around-systemic-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/evolving-topics-prostate-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-fl 2021-04-15 0.50 https://www.onclive.com/peer-exchange/evolving-treatment-paradigms-for-metastatic-liver-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/expanding-treatment-options-for-metastatic-breast-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/exploring-treatment-nsclc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/extensive-stage-sclc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/fl-evolving-research 2021-04-15 0.50 https://www.onclive.com/peer-exchange/follicular-lymphoma-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/future-directions-precision-medicine 2021-04-15 0.50 https://www.onclive.com/peer-exchange/global-perspectives-colorectal 2021-04-15 0.50 https://www.onclive.com/peer-exchange/global-sequencing-gastric-cancers 2021-04-15 0.50 https://www.onclive.com/peer-exchange/global-treatment-strategies-neuroendocrine-tumors 2021-04-15 0.50 https://www.onclive.com/peer-exchange/gu-clinical-challenges 2021-04-15 0.50 https://www.onclive.com/peer-exchange/gynecologic-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/gynecologic-cancer-recent-developments 2021-04-15 0.50 https://www.onclive.com/peer-exchange/hcc-emerging-treatment-patterns 2021-04-15 0.50 https://www.onclive.com/peer-exchange/hcc-evolving-paradigm 2021-04-15 0.50 https://www.onclive.com/peer-exchange/hcc-multidisciplinary-treatment-strategies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/hcc-treatment-global 2021-04-15 0.50 https://www.onclive.com/peer-exchange/hcl-optimizing-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/heme-malignancies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/heme-update-immunotherapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/hepatocellular-carcinoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/hodgkin-lymphoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/immunooncology-advanced-lung 2021-04-15 0.50 https://www.onclive.com/peer-exchange/immunotherapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/immunotherapy-lung-cancer-updates 2021-04-15 0.50 https://www.onclive.com/peer-exchange/immunotherapy-solid-tumors 2021-04-15 0.50 https://www.onclive.com/peer-exchange/infection-control-hematopoietic 2021-04-15 0.50 https://www.onclive.com/peer-exchange/key-issues-prostate-9 2021-04-15 0.50 https://www.onclive.com/peer-exchange/kidney-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/kidney-therapeutic-sequencing 2021-04-15 0.50 https://www.onclive.com/peer-exchange/live-cancer-armamentarium 2021-04-15 0.50 https://www.onclive.com/peer-exchange/liver-cancer-updates 2021-04-15 0.50 https://www.onclive.com/peer-exchange/looking-forward-hnscc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/lung-adenocarcinoma-approaches 2021-04-15 0.50 https://www.onclive.com/peer-exchange/lymphoid-malignancies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/lymphoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/malignant-melanoma-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/management-in-2020 2021-04-15 0.50 https://www.onclive.com/peer-exchange/management-of-cll 2021-04-15 0.50 https://www.onclive.com/peer-exchange/management-of-myeloproliferative-neoplasms 2021-04-15 0.50 https://www.onclive.com/peer-exchange/managementofbetathal 2021-04-15 0.50 https://www.onclive.com/peer-exchange/managing-cinv 2021-04-15 0.50 https://www.onclive.com/peer-exchange/managing-mtc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mbc-challenges 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mbc-community 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mbc-perspectives 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mcl-personalized-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mcrc-optimization 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mcrc-therapeutic-strategies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mds-cml 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mds-genetics 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mds-risk-complications 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mds-supportive-care 2021-04-15 0.50 https://www.onclive.com/peer-exchange/melanoma-systemic-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/melanoma-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/expert-perspectives-on-the-treatment-of-melanoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/melanoma4-advanced-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/melanoma5-malignant 2021-04-15 0.50 https://www.onclive.com/peer-exchange/metastatic-adenocarcinoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/metastatic-breast-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/metastatic-kidney-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/metastatic-melanoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/metastatic-rcc-contemporary-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mm-emerging-concepts 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mm-evolving-therapy-choice 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mm-therapeutic-approaches 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mm-treatment-2017 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mm6-management-concepts 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mnsclc-updates 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mpn-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/mrd-testing-in-all 2021-04-15 0.50 https://www.onclive.com/peer-exchange/multimodality-management-advanced-liver-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/multiple-myeloma-paradigms 2021-04-15 0.50 https://www.onclive.com/peer-exchange/myeloma-next-gen-regimens 2021-04-15 0.50 https://www.onclive.com/peer-exchange/myeloma-novel-concepts 2021-04-15 0.50 https://www.onclive.com/peer-exchange/myeloproliferative-neoplasms-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nets 2021-04-15 0.50 https://www.onclive.com/peer-exchange/neuroendocrine-tumors 2021-04-15 0.50 https://www.onclive.com/peer-exchange/new-frontier-advanced-cca 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nhl-treatment-paradigms 2021-04-15 0.50 https://www.onclive.com/peer-exchange/non-hodgkins-lymphoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-2015-update 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-advanced-trials 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-advances 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-clinical-perspectives 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-exciting-advances-in-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-io-combinations 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-needs 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-outcomes 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-perspectives-key-data 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-practice-changing-data 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-precision-medicine-recent-data 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc-therapies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/nsclc9-advances 2021-04-15 0.50 https://www.onclive.com/peer-exchange/oncology-care 2021-04-15 0.50 https://www.onclive.com/peer-exchange/optimal-management-hcc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/optimizing-liver-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/optimizing-outcomes-in-tenosynovial-giant-cell-tumors 2021-04-15 0.50 https://www.onclive.com/peer-exchange/optimizing-pv-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/optimizing-therapy-ovarian-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/optimizing-treatment-of-follicular-lymphoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/ovarian-cancer-shifting-paradigms 2021-04-15 0.50 https://www.onclive.com/peer-exchange/ovarian-cervical-cancers 2021-04-15 0.50 https://www.onclive.com/peer-exchange/ovarian-practical-essentials 2021-04-15 0.50 https://www.onclive.com/peer-exchange/pancreatic-cancer-progress 2021-04-15 0.50 https://www.onclive.com/peer-exchange/pancreatic-cancer-treatment-advances 2021-04-15 0.50 https://www.onclive.com/peer-exchange/pancreatic-highlights 2021-04-15 0.50 https://www.onclive.com/peer-exchange/pancreatic-nets 2021-04-15 0.50 https://www.onclive.com/peer-exchange/pancreatic-sequencing 2021-04-15 0.50 https://www.onclive.com/peer-exchange/pancreatic-viewpoints 2021-04-15 0.50 https://www.onclive.com/peer-exchange/peritoneal-cancer-therapies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/personalized-pancreatic-care 2021-04-15 0.50 https://www.onclive.com/peer-exchange/personalized-strategies-advanced-crc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/personalizing-prostate-cancer-therapy 2021-04-15 0.50 https://www.onclive.com/peer-exchange/pnets-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/practical-implications-lung-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/practical-perspectives-all 2021-04-15 0.50 https://www.onclive.com/peer-exchange/practical-strategies-for-treatment-of-clear-cell-renal-cell-carcinoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/precision-medicine-advanced-nsclc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/precision-medicine-aml-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/precision-medicine-nsclc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/prostate 2021-04-15 0.50 https://www.onclive.com/peer-exchange/prostate-cancer-evolving-treatment-approaches 2021-04-15 0.50 https://www.onclive.com/peer-exchange/prostate-cancer-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/prostate-cancer-treatment-advances 2021-04-15 0.50 https://www.onclive.com/peer-exchange/prostate-evolving-treatment-approaches 2021-04-15 0.50 https://www.onclive.com/peer-exchange/prostate-guidelines 2021-04-15 0.50 https://www.onclive.com/peer-exchange/prostate-therapy-review 2021-04-15 0.50 https://www.onclive.com/peer-exchange/questions-and-controversies-in-breast-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/rcc-advances 2021-04-15 0.50 https://www.onclive.com/peer-exchange/rcc-cases 2021-04-15 0.50 https://www.onclive.com/peer-exchange/rcc-practical-treatment-strategies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/rcc-sequencing-therapies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/rcc-treatment 2021-04-15 0.50 https://www.onclive.com/peer-exchange/rcc-treatment-goals 2021-04-15 0.50 https://www.onclive.com/peer-exchange/rcc-treatment-paradigm 2021-04-15 0.50 https://www.onclive.com/peer-exchange/refining-advanced-prostate-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/refining-strategies-fl 2021-04-15 0.50 https://www.onclive.com/peer-exchange/refining-therapy-cll 2021-04-15 0.50 https://www.onclive.com/peer-exchange/refractory-crc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/sabcs-evolving-treatment-patterns 2021-04-15 0.50 https://www.onclive.com/peer-exchange/sequencing-decisions-gastric-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/soft-tissue-sarcoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/squamous-nsclc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/strategies-in-kidney-cancer 2021-04-15 0.50 https://www.onclive.com/peer-exchange/sts-systemic-management 2021-04-15 0.50 https://www.onclive.com/peer-exchange/sts2-therapeutic-options 2021-04-15 0.50 https://www.onclive.com/peer-exchange/systemic-therapy-breast 2021-04-15 0.50 https://www.onclive.com/peer-exchange/systemic-therapy-mm 2021-04-15 0.50 https://www.onclive.com/peer-exchange/therapy-revolution-all 2021-04-15 0.50 https://www.onclive.com/peer-exchange/thyroid-cancer-landscape 2021-04-15 0.50 https://www.onclive.com/peer-exchange/transplant-infection-control 2021-04-15 0.50 https://www.onclive.com/peer-exchange/treating-mcrpc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/treating-tnbc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/treatment-advances-advanced-melanoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/treatment-of-acute-myeloid-leukemia 2021-04-15 0.50 https://www.onclive.com/peer-exchange/treatment-of-multiple-myeloma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/trk-inhibitors-in-lung-and-gi-cancers 2021-04-15 0.50 https://www.onclive.com/peer-exchange/trk-inhibitors-precision-medicine 2021-04-15 0.50 https://www.onclive.com/peer-exchange/unmet-needs-mbc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/updates-in-myelodysplastic-syndrome 2021-04-15 0.50 https://www.onclive.com/peer-exchange/urologist 2021-04-15 0.50 https://www.onclive.com/peer-exchange/urology-biomarkers 2021-04-15 0.50 https://www.onclive.com/peer-exchange/acute-myeloid-leukemia-evolving-perspectives-on-testing-targeted-therapies-and-transplantation 2021-04-15 0.50 https://www.onclive.com/peer-exchange/updates-in-immunotherapy-for-advanced-thoracic-malignancies 2021-04-15 0.50 https://www.onclive.com/peer-exchange/multidisciplinary-management-of-locoregional-non 2021-04-15 0.50 https://www.onclive.com/peer-exchange/advanced-breast-cancer-expert-perspectives-on-recent-progress 2021-04-15 0.50 https://www.onclive.com/peer-exchange/redefining-treatment-approaches-in-advanced-hcc 2021-04-15 0.50 https://www.onclive.com/peer-exchange/the-evolving-landscape-in-mantle-cell-lymphoma 2021-04-15 0.50 https://www.onclive.com/peer-exchange/asco-prostate-cancer-evolving-treatment-approaches 2021-04-15 0.50 https://www.onclive.com/peer-exchange/multiple-myeloma-planning-a-continuum-of-care-in-2020 2021-04-15 0.50 https://www.onclive.com/peer-exchange/hepatocellular-carcinoma-a-rapidly-evolving-treatment-landscape 2021-04-15 0.50 https://www.onclive.com/podcasts/how-this-is-building-me 2026-07-15 0.50 https://www.onclive.com/podcasts/two-onc-docs 2026-07-15 0.50 https://www.onclive.com/podcasts/oncology-unplugged 2026-07-15 0.50 https://www.onclive.com/podcasts/cancer-character-and-calling-the-oncologists-journey 2026-07-15 0.50 https://www.onclive.com/podcasts/from-discovery-to-delivery-charting-progress-in-gynecologic-oncology 2026-07-15 0.50 https://www.onclive.com/podcasts/breast-cancer-briefing 2026-07-15 0.50 https://www.onclive.com/news-network 2021-10-04 0.50 https://www.onclive.com/spanish-videos 2023-06-23 0.50 https://www.onclive.com/rapid-readouts 2026-07-15 0.50 https://www.onclive.com/podcasts/biomarker-consortium-commentary 2026-04-20 0.50